Human Embryonic Stem Cells (hESC) are extensively being researched for the use of disease eradication. HESC are pluripotent cells technology tends to be useful for tissue engineering in humans. This is owing to the high histocompatibility between the graft and the host. It shows huge potential to be the next huge medical breakthrough as the treatment for cellular loss disorders such as Type 1 diabetes mellitus, Parkinson’s disease, and lung disorders, among others.
Researchers have come up with a new method use hESC to model type 2 diabetes caused by genetic mutations could enable them to identify the drug, which could treat this disease. The use of precision medicine could target the genetic mutation, and is commonly used in treating cancer. The same approach can be hoped to be administered to treat diabetes.
Type 2 diabetes is a common condition, in which the body fails to correctly respond to the insulin (a hormone that regulates the sugar level in the blood). This results in a condition that elevates the blood sugar levels. Genomic studies scanning a set of DNA have revealed various genetic mutations implicated in diabetes.
To understand the functional role of these genetic mutations used hESCs that were used to the function like pancreatic cells; called beta-cells, produce, store, and release insulin. On further investigation, it was found that the mutation is CDKAL1, KCNQ1 and KCNJ11I was hindering the functioning of the beta cells. This caused the dwindling insulin release and issues with relating blood sugar levels. This brought forth nearly 2000 drugs under screening and found 1 compound in phase II of clinical trials that could correct CDKAL1-related defect in the beta cell.
The human embryonic stem cells market is anticipated to reach USD 1.06 billion by 2025; according to a new study by Grand View Research, Inc. Increasing cases of genetic disorders can impel the market over the coming years.
International Stem Cell Corporation, Thermo Fisher Scientific, Lonza, and LifeCell are some of the key players in the hESC market.
In-Depth research report on human embryonic stem cells market:
No comments:
Post a Comment